Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Marco Gottardis, Ph.D.

Marco Gottardis

MARCO GOTTARDIS, Ph.D.

VICE PRESIDENT
ONCOLOGY AND INNOVATION LEADER

Marco Gottardis, Ph.D. is Vice President, Oncology and Innovation Leader at Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, he is collaborating with the Data Sciences Group to explore new uses of Machine Learning and Artificial Intelligence platforms in drug discovery and competitive technology landscape analyses.

Marco is recognized as an industry and scientific leader in prostate cancer research and oncology. Prior to his current position, Marco was Prostate Cancer Disease Area Stronghold (DAS) Leader. Under his leadership, the Prostate DAS developed a significant research and development portfolio for Janssen. 

Before joining Janssen, Marco was Executive Director of Oncology and Immuno-Oncology Research and Co-leader of the Oncology Discovery Group at Bristol Myers Squibb (BMS), where he was an established leader in Oncology Discovery Research for 14 years with efforts spanning exploratory research to Investigational New Drug (IND) application candidates. He led multiple scientific teams at BMS covering diverse target areas, such as signal transduction, hormonal, immuno-oncology, apoptosis and angiogenesis in both small molecules and biologics. He was a member of the Disease Sciences and Biologics Senior Leadership Team and sat on Oncology Early Development and Commercial Strategic Teams for Prostate and Melanoma. Marco has placed multiple discovery candidates into development and has successfully led Early Development Teams that were responsible for progressing development candidates from IND to Phase 2 proof-of-concept. 

Marco has 25 years of experience as a cancer research investigator in both biotechnology and large pharmaceutical companies and more than 29 years of experience overall in translational cancer research. He has had a role in the development of multiple drug approvals in his career. These include the first approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer, the seminal pre-clinical studies leading to the development of tamoxifen as a chemo-preventive therapy for breast cancer and the approval of selective estrogen receptor modulators, retinoid and retinoid x  receptor (RXR) drugs for cancer while he was a Senior Investigator at LIGAND Pharmaceuticals in San Diego. 

Marco obtained his Bachelor of Science from Columbia College, Columbia University and his doctorate at the Wisconsin Clinical Cancer Center, University of Wisconsin. He completed his post-doctoral fellowship at Vincent T Lombardi Cancer Center, Georgetown University. He has co-authored more than 100 publications and is co-inventor on multiple patents.